Trial Profile
An Open-Label, Multicenter, Phase 1a/1b Study of Olaratumab (LY3012207) Plus Pembrolizumab (MK3475) in Patients With Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma (STS) Who Have Failed Standard Treatments
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Apr 2023
Price :
$35
*
At a glance
- Drugs Olaratumab (Primary) ; Pembrolizumab (Primary)
- Indications Liposarcoma; Soft tissue sarcoma
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 12 Apr 2023 Status changed from active, no longer recruiting to completed.
- 19 Jul 2022 Planned End Date changed from 28 Apr 2022 to 26 May 2023.
- 19 May 2021 Planned End Date changed from 28 Apr 2021 to 28 Apr 2022.